These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 7749047)

  • 1. Virus validation of plasma-derived products produced by Pharmacia, with particular reference to immunoglobulins.
    Eriksson B; Westman L; Jernberg M
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S37-44. PubMed ID: 7749047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
    Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
    Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of manufacturing process parameters on virus inactivation by solvent-detergent treatment in a high-purity factor IX concentrate.
    Roberts PL; Dunkerley C
    Vox Sang; 2003 Apr; 84(3):170-5. PubMed ID: 12670365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with the viral safety of immunoglobulins.
    Hellstern P
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S31-4; discussion S35. PubMed ID: 7749046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Possibilities of virus inactivation of pooled fresh plasma with tri-n-butylphosphate (TNBP) detergents (SD procedure)].
    Gürtler L
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():77-9. PubMed ID: 8000260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
    Goldsmith JC
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin.
    Uemura Y; Yang YH; Heldebrant CM; Takechi K; Yokoyama K
    Vox Sang; 1994; 67(3):246-54. PubMed ID: 7863623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable virus inactivation by bovine or vegetable derived Tween 80 during solvent/detergent treatment.
    Seitz H; Blümel J; Schmidt I; Willkommen H; Löwer J
    Biologicals; 2002 Sep; 30(3):197-205. PubMed ID: 12217344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
    Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
    Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of an additional viral-clearance step into a human immunoglobulin manufacturing process.
    Van Holten RW; Ciavarella D; Oulundsen G; Harmon F; Riester S
    Vox Sang; 2002 Oct; 83(3):227-33. PubMed ID: 12366764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral safety of solvent/detergent-treated blood products.
    Horowitz B; Prince AM; Hamman J; Watklevicz C
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S21-8; discussion S29-S30. PubMed ID: 7749045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.
    Korneyeva M; Hotta J; Lebing W; Rosenthal RS; Franks L; Petteway SR
    Biologicals; 2002 Jun; 30(2):153-62. PubMed ID: 12127317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products.
    Remington KM; Trejo SR; Buczynski G; Li H; Osheroff WP; Brown JP; Renfrow H; Reynolds R; Pifat DY
    Vox Sang; 2004 Jul; 87(1):10-8. PubMed ID: 15260817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Indications for fresh frozen plasma: evaluation of virus inactivating preparations].
    Pindur G; Kiesewetter H; Seyfert UT; Wenzel E
    Beitr Infusionsther; 1993; 31():74-80. PubMed ID: 7693268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral safety of solvent/detergent-treated plasma.
    Solheim BG; Rollag H; Svennevig JL; Arafa O; Fosse E; Bergerud U
    Transfusion; 2000 Jan; 40(1):84-90. PubMed ID: 10644817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solvent/detergent treatment of human plasma--a very robust method for virus inactivation. Validated virus safety of OCTAPLAS.
    Biesert L; Suhartono H
    Vox Sang; 1998; 74 Suppl 1():207-12. PubMed ID: 9789530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus validation studies of immunoglobulin preparations.
    Biesert L
    Clin Exp Rheumatol; 1996; 14 Suppl 15():S47-52. PubMed ID: 8828948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The Ad Hoc Study Group of the Fondazione dell'Emofilia.
    Mariani G; Di Paolantonio T; Baklaya R; Morfini M; Mannucci PM
    Transfusion; 1993 Oct; 33(10):814-8. PubMed ID: 8236421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Issues in the development of medical products based on human plasma.
    Josić D; Schulz P; Biesert L; Hoffer L; Schwinn H; Kordis-Krapez M; Strancar A
    J Chromatogr B Biomed Sci Appl; 1997 Jul; 694(2):253-69. PubMed ID: 9252039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.